Regeneron Pharmaceuticals Inc REGN Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$904.35 up $1.45, 0.16% at close Nov 6
Last close · Previous close $902.90
- Market cap
- $93.11BAt the Nov 6 close
- P/E ratio
- 19.96On last 12 months’ EPS
- Diluted EPS
- $45.30Last 12 months
- Dividend yield
- 0.41%Last 12 months
Price chart
$904.35up $1.45, 0.16%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$902.90Nov 5
- Volume1.12MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume916.84KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $591.52 to $991.73; now $904.35
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
REGN beat the S&P 500 in 4 of 7 periods.
| Period | REGN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | REGN: up 22.4% S&P 500: down 5.6% | REGN beat the S&P 500 by 28.0 percentage points Beat |
| 3M | REGN: up 17.3% S&P 500: down 4.1% | REGN beat the S&P 500 by 21.4 percentage points Beat |
| YTD | REGN: up 17.6% S&P 500: up 8.7% | REGN beat the S&P 500 by 8.9 percentage points Beat |
| 1Y | REGN: up 40.5% S&P 500: up 10.9% | REGN beat the S&P 500 by 29.6 percentage points Beat |
| Long term | ||
| 3Y | REGN: up 9.6% S&P 500: up 75.0% +3.1% vs +20.5% a year | REGN trailed the S&P 500 by 65.4 percentage points Trailed |
| 5Y | REGN: up 49.3% S&P 500: up 67.8% +8.3% vs +10.9% a year | REGN trailed the S&P 500 by 18.5 percentage points Trailed |
| 10Y | REGN: up 167.4% S&P 500: up 313.1% +10.3% vs +15.2% a year | REGN trailed the S&P 500 by 145.7 percentage points Trailed |
$10,000 invested in REGN 10 years ago (Nov 4, 2016) would be worth about $26,736 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
REGN beat the S&P 500 in 4 of 7 periods.
| Period | REGN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | REGN: up 22.4% S&P 500: down 5.6% | REGN beat the S&P 500 by 28.0 percentage points Beat |
| 3M | REGN: up 17.1% S&P 500: down 4.3% | REGN beat the S&P 500 by 21.4 percentage points Beat |
| YTD | REGN: up 17.2% S&P 500: up 7.8% | REGN beat the S&P 500 by 9.4 percentage points Beat |
| 1Y | REGN: up 39.8% S&P 500: up 9.7% | REGN beat the S&P 500 by 30.1 percentage points Beat |
| Long term | ||
| 3Y | REGN: up 8.6% S&P 500: up 68.8% +2.8% vs +19.1% a year | REGN trailed the S&P 500 by 60.2 percentage points Trailed |
| 5Y | REGN: up 47.9% S&P 500: up 56.9% +8.1% vs +9.4% a year | REGN trailed the S&P 500 by 9.0 percentage points Trailed |
| 10Y | REGN: up 164.9% S&P 500: up 252.6% +10.2% vs +13.4% a year | REGN trailed the S&P 500 by 87.7 percentage points Trailed |
$10,000 invested in REGN 10 years ago (Nov 4, 2016) would be worth about $26,490 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$1,201.76
Closing high on . Now 24.7% below that record.
Split-adjusted daily closes since Apr 2, 1991.
Stock splits
REGN hasn’t split since its price history begins in 1991.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Sep 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
20.0×The Nov 6 close ÷ diluted EPS over the last 12 months ($45.30)
The range covers daily P/E ratios from Oct 28, 2021 to Nov 6, 2026, each based on the previous 12 months of earnings.
REGN trades at 20.0× its earnings over the last 12 months, above its 5-year median of 17.5×. In plain terms, buyers are paying about $20 for each $1 of profit from the past year. How to read P/E
Other valuation measures
- 5.5×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 2.8×Book value as of Sep 30, 2026
Price relative to accounting equity (book value) per share on the Sep 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - 13.9×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - 2.39Last 12 months’ EPS growth
The P/E divided by the growth in diluted EPS over the last 12 months (+8.3% on the 12 months before). It looks backward: near 1 means the P/E roughly matches last year’s growth. Sites that use analysts’ growth forecasts show a different PEG.
PEG = P/E ÷ EPS growth (%) = 20.0 ÷ 8.3 - 4.11%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $86.51BAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Sep 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own REGN DCF in Excel. Value Regeneron Pharmaceuticals with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $16.90Bup 18.6%
- Net income
- $4.82Bup 5.2%
- Diluted EPS
- $45.30up 8.3%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $3.79B | $917.70M | $8.11 |
| Q1 FY25 (Mar 31, 2025) | $3.03B | $808.70M | $7.27 |
| Q2 FY25 (Jun 30, 2025) | $3.68B | $1.39B | $12.81 |
| Q3 FY25 (Sep 30, 2025) | $3.75B | $1.46B | $13.62 |
| Q4 FY25 (Dec 31, 2025) | $3.88B | $844.60M | $7.87 |
| Q1 FY26 (Mar 31, 2026) | $3.61B | $727.20M | $6.75 |
| Q2 FY26 (Jun 30, 2026) | $4.29B | $1.30B | $12.23 |
| Q3 FY26 (Sep 30, 2026) | $5.12B | $1.95B | $18.45 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $16.07B | $8.08B | $71.97 |
| FY22 (Dec 31, 2022) | $12.17B | $4.34B | $38.22 |
| FY23 (Dec 31, 2023) | $13.12B | $3.95B | $34.77 |
| FY24 (Dec 31, 2024) | $14.20B | $4.41B | $38.34 |
| FY25 (Dec 31, 2025) | $14.34B | $4.50B | $41.48 |
Margins
- Gross 85.8%
- Operating 28.8%
- Net 28.5%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $3.83BLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$4.85BLast 12 months
- Capital spending$1.02BLast 12 months
- 22.6%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $2.71BLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$383.00MLast 12 months
- Total returned$3.10BLast 12 months
81% of free cash flow
Balance sheet
- $18.86BAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$2.71BAs of Sep 30, 2026
- Net cash$16.15BAs of Sep 30, 2026
- 3.35As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.08As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 7 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✓Share count didn’t rise: passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 15.1%Last 12 months
Over the last 12 months, Regeneron Pharmaceuticals’s net income was 15.1% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 11.5%Last 12 months
Over the last 12 months, Regeneron Pharmaceuticals’s net income was 11.5% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $0.000 |
| 2017 | $0.000 |
| 2018 | $0.000 |
| 2019 | $0.000 |
| 2020 | $0.000 |
| 2021 | $0.000 |
| 2022 | $0.000 |
| 2023 | $0.000 |
| 2024 | $0.000 |
| 2025 | $3.52 |
| 2026 (to date) | $2.82 |
Dividend details
- $3.70Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- 0.41%; 5-yr low 0.12%, 5-yr high 0.70%Last 12 months
Dividends paid over the last 12 months as a share of the Nov 6 close. The bar shows where that yield sits in its range over the past five years; the median was 0.46%.
- $0.94Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
- FrequencyQuarterly4 payments in the last 12 months
- 8.2%Last 12 months
The share of earnings paid out as dividends over the last 12 months. Lower ratios leave more room to reinvest or raise the dividend.
Payout = Dividends per share ÷ Diluted EPS (both last 12 months)Payout ratio calculator
About Regeneron Pharmaceuticals Inc
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite ®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
REGN news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
REGN stock FAQ
What is REGN stock’s price today?
Regeneron Pharmaceuticals (REGN) traded at $904.35 at the close on , up $1.45 (0.16%) from the previous close of $902.90. Over the past 52 weeks it has traded between $591.52 and $991.73.
If you invested $1,000 in REGN 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in REGN on would be worth about $2,674 at the close on , a total return of +167.4%. The same $1,000 would be worth $1,493 if invested five years ago, $1,405 if invested one year ago, $39,308 if invested 20 years ago, and $48,679 if invested 30 years ago. Past performance doesn’t predict future returns.
What is Regeneron Pharmaceuticals’s market cap?
Regeneron Pharmaceuticals’s market capitalization is about $93.1 billion. That’s Tiingo’s daily market cap for , at that day’s closing price of $904.35 (how market cap works). Regeneron Pharmaceuticals reported 102.95M shares outstanding at the end of its latest quarter ().
What is REGN’s P/E ratio?
REGN trades at 20.0 times its diluted earnings over the four quarters to ($45.30 per share), at the close. Over the past five years its P/E has ranged from 7.5 to 30.6, with a median of 17.5. (How the P/E ratio works.)
How much revenue does Regeneron Pharmaceuticals make?
Regeneron Pharmaceuticals reported $16.9 billion of revenue over the four quarters to , up 18.6% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $5.1 billion, up 36.3% from a year earlier.
Is Regeneron Pharmaceuticals profitable?
Yes. Regeneron Pharmaceuticals earned $4.8 billion of net income over the four quarters to , a net margin of 28.5%, and its operating margin was 28.8% (what margins tell you).
What are REGN’s earnings per share?
REGN’s diluted earnings per share were $45.30 over the four quarters to , compared with $41.81 in the twelve months before. The latest quarter (Q3 FY26) brought $18.45 per share, against $13.62 a year earlier (how EPS works).
Does REGN pay a dividend?
Yes. Regeneron Pharmaceuticals pays a quarterly dividend. The most recent was $0.94 per share, with an ex-dividend date of . Over the last twelve months it paid $3.70 per share, a 0.41% yield at the close (how dividend yield works).
Based on the last 12 months’ payments ($3.70 per share), and if the next 12 months match the last 12, 100 shares would receive about $370 over 12 months, and $1,000 over 12 months would take about 271 shares, roughly $245,079 at the close. Dividends can change.
What is REGN’s 52-week high and low?
Over the past 52 weeks REGN has traded as low as $591.52 and as high as $991.73. At $904.35 at the close on , it is 8.8% below that high and 52.9% above the low.
What is REGN’s all-time high?
REGN’s highest closing price was $1,201.76 on , adjusted for stock splits. At $904.35 at the close on , it is 24.7% below that record.
Has REGN stock ever split?
No. REGN hasn’t split since its price history begins in 1991.
How has REGN stock performed?
Including dividends and measured to the close on , REGN has returned +17.6% so far this year and +40.5% over the past year, and +49.3% over five years (+8.3% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Regeneron Pharmaceuticals in?
Regeneron Pharmaceuticals is in the Healthcare sector and the Biotechnology industry, and is headquartered in New York, USA.
What exchange does REGN trade on?
Regeneron Pharmaceuticals trades on the Nasdaq under the ticker symbol REGN. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.